View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 27, 2016updated 13 Jul 2022 10:13am

Neurovance reports positive results from Phase IIb trial of CTN to treat ADHD

US-based, clinical stage, neuroscience-focused company Neurovance has reported a positive outcome for the Phase IIb trial of centanafadine SR (CTN) to treat adults with attention-deficit / hyperactivity disorder (ADHD).

US-based, clinical stage, neuroscience-focused company Neurovance has reported a positive outcome for the Phase IIb trial of centanafadine SR (CTN) to treat adults with attention-deficit / hyperactivity disorder (ADHD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

CTN is a non-stimulant controlling the activity of norepinephrine (NE), dopamine (DA) and serotonin (5-HT), three neurotransmitters considered to be responsible for the disorder.

The Phase IIb trial was a placebo-controlled crossover study conducted over a period of three weeks.

A total of 85 adult ADHD patients were involved in the trial and administered with CTN on a twice daily regimen.

"Results displayed that CTN had the same effect as a non-stimulant when compared with the effects of the approved stimulants."

The trial was designed to determine the safety and efficacy of CTN in treating ADHD.

Results displayed that CTN had the same effect as a non-stimulant when compared with the effects of the approved stimulants.

The 400mg dosage of CTN has also demonstrated tolerability with lesser rates of insomnia and loss of appetite when compared with stimulants.

Neurovance president and CEO Anthony McKinney said: “We believe that CTN is among the first of a new generation of triple reuptake inhibitors in advanced development for ADHD and these study results are critical to establishing the dose range and regulatory path forward for centanafadine.

“Based on previous data we have shown, CTN had an efficacy profile approaching that of stimulants, yet with human trial results suggesting less risk of abuse.”

Based on the data from the Phase II trial, the company is planning to conduct the Phase III trial of CTN to support the US Food and Drug Administration (FDA) approval.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena